

## Patient Group Direction (PGD)

# Supply of Fusidic Acid 2% Cream Version – 2.0

The purpose of the PGD is to allow management of impetigo in adults and children by registered pharmacists in Community Pharmacies.

This PGD authorises pharmacists delivering the NHS Pharmacy First Scotland Service Level Agreement to supply Fusidic acid 2% cream to adults and children presenting with symptoms of impetigo who meet the criteria for inclusion under the terms of the document.

NICE Guideline 153<sup>1</sup> recommends that hydrogen peroxide 1% cream should be considered as first line treatment for patients with localised non-bullous impetigo who are not systemically unwell or at high risk of complications. Hydrogen peroxide 1% cream (Crystacide) is listed on the NHS PFS Approved List.

Please refer to your local Health Board policy for first line treatment of impetigo.

#### Change History – see table at end of this document for more details

- Removal of lower age limit
- Minor changes to inclusion criteria
- Minor changes to exclusion criteria
- Clarification of symptoms
- Additional safety netting advice included

If this PGD is past the review date, the content shall remain valid until such time that the review is complete and a new version has been published. <u>It is the responsibility of the person using the PGD to ensure they are using the most recent issue.</u>

<u>1</u>. National Institute for Health and Care Excellence. *Guideline 153 Impetigo : antimicrobial prescribing*. February 2020. Available at: Impetigo: antimicrobial prescribing (nice.org.uk) (accessed 16th June 2022)

#### PGD Fusidic Acid Cream 2%

#### Authorisation

This Patient Group Direction (PGD) has been produced in collaboration with the Scottish Antimicrobial Prescribing Group and the Primary Care Community Pharmacy Group to assist NHS Boards in the provision of uniform services under the 'NHS Pharmacy First Scotland' banner across NHS Scotland. NHS Borders has ensured that the final PGD is considered and approved in line with local clinical governance arrangements for PGDs.

The qualified health professionals who may supply Fusidic Acid 2% cream under this PGD can only do so as named individuals. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their own Code of Professional Conduct, and to ensure familiarity with the marketing authorisation holder's summary of product characteristics (SPC) for all medicines supplied in accordance with this PGD.

NHS board governance arrangements will indicate how records of staff authorised to operate this PGD will be maintained. Under PGD legislation there can be no delegation. Supply of the medicine has to be by the same practitioner who has assessed the patient under the PGD.

۸

#### This specimen PGD has been approved on behalf of NHS Scotland by NHS 24 by:

Doctor	Dr Laura Ryan	Signature	Lance Rys
Pharmacist	Dr John McAnaw	Signature	John July 4 man
NHS Scotland Representative	Mr Jim Miller	Signature	for hardles
Approved on behalf	of NHS Borders by:		
Medical Director	Dr Lynn McCallum	Signature	- lyuulllolluun
Director of Pharmacy/Senior Pharmacist	Alison Wilson	Signature	ACUilan
Clinical Governance Lead	Sarah Horan	Signature	Stre
Date approved	12/09/2022		
Effective from date	August 2022	- Review date	August 2024

NHS Pharmacy First Scotland PGD Fusidic Acid 2% Cream Version 2.0 August 2022

#### **Clinical Situation**

Clinical Situation				
Indication	Treatment of minor staphylococcal skin infections. (Impetigo)			
Inclusion Criteria	<ul> <li>Adults and children with minor/localised, uncomplicated skin infection</li> <li>The rash consists initially of vesicles with erythematous base which easily rupture and are seldom observed. The exudate dries to form yellow-gold or yellow-brown crust which gradually thickens</li> <li>Informed consent by patient or parent/carer</li> <li>Patient must be present at consultation</li> </ul>			
Exclusion Criteria	<ul> <li>Widespread skin infection.</li> <li>History of MRSA colonisation or infection</li> <li>Has had impetigo treated with an antibiotic (including fusidic acid 2% cream) within the last 3 months.</li> <li>Patient systemically unwell</li> <li>Allergy to any component of the cream.</li> <li>Patient/carer refuses treatment.</li> <li>Presenting with any underlying skin condition on the same area of the body as impetigo.</li> </ul>			
Cautions /Need for further advice/ Circumstances when further advice should be sought from a doctor	<ul> <li>Any doubt as to inclusion/exclusion criteria being met.</li> <li>Lesions present near the eye – care should be taken when applying cream near to the eye.</li> <li>Patients under one year of age – in some cases, impetigo management may require oral (or sometimes IV) antibiotics, especially in neonates. These children may need clinical review therefore appropriate safety-netting advice is essential e.g. if not improving, see GP.</li> </ul>			
Action if Excluded	Refer to GP Practice/Out-of-hours (OOH) service and document in Patient Medication Record (PMR)			
Action if Patient Declines`	If patient declines treatment, advise on self-care to relieve symptoms and advise to see their GP if symptoms fail to resolve within 5 days or if symptoms worsen. Advise to contact NHS 24 if becoming systemically unwell or rapidly spreading to large areas of body during OOH period. The reason for declining treatment and advice given must be documented. Ensure patient is aware of risks and consequences of declining treatment. Record outcome in Patient Medication Record (PMR) if appropriate.			

I

#### **Description of Treatment**

Description of Treatment				
Name of Medicine	Fusidic Acid			
Form/Strength	2% Cream			
Route of	Topical			
administration				
Dosage	Apply gently to lesions			
Frequency	Apply three or four times daily			
Duration of treatment	5 days			
Maximum or minimum	Use for a maximum of 5 days. Maximum of one supply in three			
treatment period	months.			
Quantity to	1 x 15g			
supply/administer				
additional	No			
monitoring				
Legal Category	POM (Prescription Only Medicine)			
Is the use outwith the SPC	No			
Storage requirements	As per manufacturer's instructions			
	Store below 25°C in a cool dry place			
Additional information	None			

Warnings including possible adverse reactions and management of these	Side effects with this product are rare however hypersensitivity reactions may occur. For a full list of side effects – refer to the marketing authorisation holder's Summary of Product Characteristics (SPC). A copy of the SPC must be available to the health professional administering medication under this PGD. This can be accessed on <u>Home - electronic medicines compendium (emc)</u>
Reporting procedure for adverse reactions	<ul> <li>Pharmacists should document and report all adverse incidents through their own internal governance systems.</li> <li>All adverse reactions (actual and suspected) should be reported to the appropriate medical practitioner and recorded in the patient's medical record. Pharmacists should record in their PMR and inform the patient's GP as appropriate (e.g. via SBAR).</li> <li>Where appropriate, use the Yellow Card System to report adverse drug reactions. Yellow Cards and guidance on its use are available at the back of the BNF or online at <a href="http://yellowcard.mhra.gov.uk/">http://yellowcard.mhra.gov.uk/</a></li> </ul>
Advice to Patient/carer including written information	<ul> <li>Wash hands before and after applying cream.</li> <li>Where possible remove scabs by bathing with warm water before applying the cream.</li> <li>Impetigo is a very infectious condition. Important to prevent infection spreading by using own flannels and towels (hot wash after use).</li> <li>Do not scratch or pick spots.</li> </ul>

Monitoring	<ul> <li>If applicable, suggest applying cream three times daily on school days (before school, after school and evening) and four times daily at other times.</li> <li>Inform school of condition. Advise that child should be excluded from school until the lesions are crusted and healed or 48 hours after commencing antibiotic treatment.</li> <li>Do not share cream with anyone else.</li> <li>Do not apply to breast if patient is breastfeeding.</li> <li>Inform of possible side effects and their management. The Drug Manufacturer Patient Information Leaflet should be given. Patients should be informed who to contact should they experience an adverse drug reaction</li> </ul>
Monitoring Follow-up	Not applicable If the skin infection spreads or there is no improvement after 5 days, seek medical advice from GP. If patient becomes systemically unwell or rapidly spreading to large areas of body during OOH period seek medical advice from NHS 24.
Additional Facilities	<ul> <li>The following should be available where the medication is supplied:</li> <li>An acceptable level of privacy to respect patient's right to confidentiality and safety.</li> <li>Access to medical support (this may be via the telephone).</li> <li>Clean and tidy work areas, including access to hand washing facilities.</li> <li>Access to current BNF (online version preferred).</li> </ul>

#### Characteristics of staff authorised under the PGD

Professional qualifications	Registered pharmacist with current General Pharmaceutical Counci (GPhC) registration.		
1	Under PGD legislation there can be no delegation. Supply of		
	the medication has to be by the same practitioner who has		
	assessed the patient under this PGD.		
Specialist	Has successfully completed NES Pharmacy "Impetigo for NHS		
competencies or	Pharmacy First Scotland" e-learning module.		
qualifications	Available at:		
	https://learn.nes.nhs.scot/34440/pharmacy/cpd-		
	resources/impetigo-for-nhs-pharmacy-first-scotland		
	Able to assess the person's capacity to understand the nature and purpose of the medication in order to give or refuse consent.		
	Must be familiar with the Fusidic Acid Cream Summary of Product Characteristics (SPC).		
Continuing education and training	Has read current guidance on the management of impetigo Aware of local treatment recommendations.		
	Attends approved training and training updates as appropriate. Undertakes CPD when PGD or NES Pharmacy module updates.		

I

Audit Trail	
Record/Audit Trail	<ul> <li>All records must be clear, legible and in an easily retrieval format. Pharmacists must record in Patient Medication Record (PMR). The following records should be kept (paper or computer based) and are included in the patient assessment form:</li> <li>Patient's name/parent/guardian/person with parental responsibility, address, date of birth and consent given</li> <li>Patient's CHI number</li> <li>Contact details of GP (if registered)</li> <li>Presenting complaint and diagnosis</li> <li>Details of medicine supplied</li> <li>The signature and printed name of the healthcare professional who supplied the medicine.</li> <li>Advice given to patient (including side effects)</li> <li>Whether the patient met the inclusion criteria and whether the exclusion criteria were assessed</li> <li>Details of any adverse drug reaction and actions taken including documentation in the patient's medical record</li> <li>Referral arrangements (including self-care)</li> </ul> These records should be retained in accordance with national guidance <sup>2</sup> (see page 56 for standard retention periods summary table). Where local arrangements differ, clarification should be obtained through your Health Board Information Governance Lead. All records of the drug(s) specified in this PGD will be filed with the normal records of medicines in each service. A designated person within each service will be responsible for auditing completion of drug forms and collation of data. 2. Sottish Government. Scottish Government Records Management. Edinburgh 2020. Available at SG-HSC-Scottand-Records Management. Edinburgh 2020. Avaliable at SG-HSC-Scottand-Records Managemen
	British National Formulary (BNF) current edition Fusidic Acid Cream SPC

### Version history

Version	Date	Summary of Changes
1.0	April 2020	Version 1.0 New PGD
2.0	August 2022	<ul> <li>The following sections have been updated:</li> <li>Addition of statement regarding first line treatment of non-bullous impetigo for patients who are not systemically unwell or at high risk of complications – refer to local Health Board policy on use of hydrogen peroxide 1% cream (Crystacide)</li> <li>Addition of covering statement regarding validity of PGD when approaching date for review of content</li> <li>Removal of lower age limit of 2 years</li> <li>Changes to inclusion criteria to clarify symptoms of impetigo</li> <li>Amendment of exclusion criteria from multiple site to widespread infection</li> <li>Removal of "concern about non-compliance with topical treatment" exclusion</li> <li>Update to guidance for children at school to minimise risk of spread of infection</li> <li>Addition of guidance on follow up required when patient becomes systemically unwell during OOH period</li> </ul>

#### PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID 2% CREAM BY COMMUNITY PHARMACISTS UNDER THE "NHS PHARMACY FIRST SCOTLAND" SERVICE

#### Individual Authorisation

#### PGD does not remove inherent professional obligations or accountability

It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with the General Pharmaceutical Council Standards for Pharmacy Professionals.

**Note to Authorising Authority:** authorised staff should be provided with access to the clinical content of the PGD and a copy of the document showing their authorisation.

I have read and understood the Patient Group Direction authorised by each of the individual NHS Boards that I wish to operate in and agree to provide Fusidic Acid 2% cream.

Name of Pharmacist

GPhC Registration Number

#### Normal Pharmacy Location

(Only one Pharmacy name and contractor code is required for each Health Board (HB) area where appropriate. If you work in more than 3 HB areas please use additional forms.)

Name & Contractor code HB (1)	
Name & Contractor code HB (2)	
Name & Contractor code HB (3)	

Please indicate your position within the pharmacy by ticking one of the following:

Locum	Empl	oyee N	/lanag	er	Owne	er 🗌
Signature			Date			
Please tick and sen addresses are given of			you	work	in. Fax numbers	, email and postal
Ayrshire & Arran		Grampian			Orkney	
Borders		Gr Glasgow & Cly	yde		Shetland	
Dumfries & Galloway		Highland			Tayside	
Fife		Lanarkshire			Western Isles	
Forth Valley		Lothian				

NHS Pharmacy First Scotland

PGD Fusidic Acid 2% Cream Version 2.0 August 2022

NHS Board	Address	Fax Number
Ayrshire & Arran	Iain Fulton, NHS Ayrshire & Arran, Eglington House, Ailsa Hospital, Dalmellington Road, Ayr, KA6 6AB margaret.scott3@aapct.scot.nhs.uk	Please email or post
Borders	Community Pharmacy Team Pharmacy Department, Borders General Hospital, Melrose, TD6 9BS communitypharmacy.team@borders.scot.nhs.uk	Please email or post
Dumfries & Galloway	NHS Dumfries & Galloway, Primary Care Development, Ground Floor North, Mountainhall Treatment Centre, Bankend Rd, Dumfries, DG1 4TG Dg.pcd@nhs.scot	Please email or post
Fife	PGD Administrator, Pharmacy Services, NHS Fife, Pentland House, Lynebank Hospital, Halbeath Road, Dunfermline, KY11 4UW Fife.pgd@nhs.scot	Please email or post
Forth Valley	Community Pharmacy Development Team, Forth Valley Royal Hospital, Stirling Road, Larbert, FK5 4WR fv.communitypharmacysupport@nhs.scot	Please email or post
Grampian	Pharmaceutical Care Services Team NHS Grampian, Pharmacy & Medicines Directorate, Westholme, Woodend, Queens Road, Aberdeen, AB15 6LS <u>gram.pharmaceuticalcareservices@nhs.scot</u>	Please email or post
Greater Glasgow & Clyde	Janine Glen, Contracts Manager, Community Pharmacy, NHS Greater Glasgow & Clyde, Clarkston Court, 56 Busby Road, Glasgow G76 7AT ggc.cpdevteam@nhs.scot	0141 201 6044 Or email
Highland	Community Pharmaceutical Services, NHS Highland, Assynt House, Beechwood Park, Inverness. IV2 3BW <u>nhsh.cpsoffice@nhs.scot</u>	Please email or post
Lanarkshire	Pharmacy/Prescribing Admin Team, NHS Lanarkshire Headquarters, Kirklands, Fallside Road, Bothwell, G71 8BB <u>Pharmacy.AdminTeam@lanarkshire.scot.nhs.uk</u>	Please email or post
Lothian	Primary Care Contractor Organisation, 2 <sup>ND</sup> Floor, Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG <u>CommunityPharmacy.Contract@nhslothian.scot.nhs.uk</u>	Please email or post
Orkney	Lyndsay Steel, Lead General Practice Pharmacist. The Balfour, Foreland Road, Kirkwall, KW15 1NZ Phone: 01856 888 911 ork.primarycarepharmacy@nhs.scot	Please email or post
Shetland	Mary McFarlane, Principle Pharmacist, NHS Shetland, Gilbert Bain Hospital, Lerwick, Shetland, ZE1 0TB	01595 743356
Tayside	Diane Robertson Pharmacy Department, East Day Home, Kings Cross Hospital, Clepington Road, Dundee, DD3 8AE <u>Diane.Robertson9@nhs.scot</u>	Please email or post
Western Isles	Michelle Taylor, Primary Care Dept, The Health Centre, Springfield Road, Stornoway, Isle of Lewis, HS1 2PS	Please post